Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Integra LifeSciences Holdings Corporation (IART)

14.82 +1.19 (+8.73%)
At close: November 4 at 4:00:01 PM EST
14.82 0.00 (0.00%)
Pre-Market: 4:39:35 AM EST
Trade IART on Coinbase
Chart Range Bar
Loading chart for IART
  • Previous Close 13.63
  • Open 13.97
  • Bid 10.65 x 200
  • Ask 17.92 x 200
  • Day's Range 13.84 - 15.15
  • 52 Week Range 8.70 - 20.49
  • Volume 1,174,233
  • Avg. Volume 977,723
  • Market Cap (intraday) 1.153B
  • Beta (5Y Monthly) 1.28
  • PE Ratio (TTM) 87.18
  • EPS (TTM) 0.17
  • Earnings Date Oct 21, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 15.67
  • Zacks Rating Bearish

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

www.integralife.com

4,427

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IART
19.32%
S&P 500 (^GSPC)
12.32%

1-Year Return

IART
31.15%
S&P 500 (^GSPC)
13.54%

3-Year Return

IART
61.75%
S&P 500 (^GSPC)
76.41%

5-Year Return

IART
79.24%
S&P 500 (^GSPC)
64.28%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 411.18M
Earnings 14.85M
Profit Margin 3.61%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
100M
200M
300M
400M
-1.0%
0.0%
1.0%
2.0%
3.0%

Analyst Insights

View More

Analyst Price Targets

13.00 Low
15.67 Average
14.82 Current
23.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst UBS
Rating Action Maintains
Rating Neutral
Price Action Lowers
Price Target 19 -> 14

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.79%

  • Return on Assets (ttm)

    2.86%

  • Return on Equity (ttm)

    1.24%

  • Revenue (ttm)

    1.66B

  • Net Income Avi to Common (ttm)

    13.01M

  • Diluted EPS (ttm)

    0.17

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    311.93M

  • Total Debt/Equity (mrq)

    187.81%

  • Levered Free Cash Flow (ttm)

    106.28M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: